Follow-up care after treatment is critical and typically includes regular physical examinations, imaging studies when indicated, and monitoring for symptoms of recurrence or treatment-related side effects, as early detection of recurrence can open the door to additional treatment options and better outcomes. Throughout the treatment journey, patient education, shared decision-making, and clear communication between patients and healthcare providers play a vital role in empowering individuals to understand their diagnosis, treatment options, potential risks and benefits, and expected outcomes, enabling them to make informed choices that align with their values and life goals. Advances in research continue to improve uterine cancer treatment, with ongoing clinical trials exploring new drug combinations, novel targeted agents, immunotherapies, and less invasive surgical and radiation techniques, offering hope for improved survival rates, fewer side effects, and better quality of life for patients now and in the future, and as our understanding of the genetic and molecular basis of uterine cancer deepens, treatment strategies are becoming increasingly tailored, moving away from a one-size-fits-all approach toward more precise, effective, and patient-centered care that recognizes each individual’s unique situation and needs.

Uterine cancer treatment is a multifaceted and highly individualized process that depends on the type and stage of the cancer, the patient’s overall health, age, fertility considerations, genetic factors, and personal preferences, and it typically involves one or a combination of surgery, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and immunotherapy, all coordinated by a multidisciplinary medical team to achieve the best possible outcome while preserving quality of life. In most cases, especially for endometrial cancer which is the most common form of uterine cancer, surgery is the primary and often first-line treatment, usually involving a total hysterectomy where the uterus is removed along with the cervix, and frequently accompanied by a bilateral salpingo-oophorectomy, which means removal of both ovaries and fallopian tubes to reduce the risk of cancer spread or recurrence, and during this procedure lymph nodes in the pelvis and sometimes around the aorta may also be sampled or removed to determine whether the cancer has spread beyond the uterus, a step that is critical for accurate staging and planning further treatment.

Minimally invasive surgical approaches such as laparoscopy or robotic-assisted surgery are increasingly used when appropriate because they are associated with less pain, shorter hospital stays, reduced blood loss, and faster recovery compared to traditional open surgery, although open abdominal surgery may still be necessary in advanced cases or when the cancer has extensively spread. For patients diagnosed at an early stage, surgery alone may be sufficient and curative, particularly when the cancer is low-grade and confined to the uterine lining, but when pathological examination reveals higher-risk features such as deep invasion into the uterine muscle, involvement of lymphovascular spaces, high-grade tumor cells, or spread to lymph nodes, additional treatments are often recommended to reduce the Best Gyneconcolgist in chenna of recurrence. Radiation therapy is commonly used either after surgery as adjuvant treatment or, in some cases, as a primary treatment when surgery is not possible due to medical reasons, and it works by using high-energy rays to destroy remaining cancer cells in the pelvis or vaginal area, with external beam radiation therapy targeting a broader pelvic region and brachytherapy, or internal radiation, delivering radiation directly to the vaginal cuff through a specialized applicator to minimize exposure to surrounding tissues.

Radiation therapy can significantly reduce local recurrence rates, especially in intermediate- and high-risk patients, but it may be associated with side effects such as fatigue, skin irritation, changes in bowel or bladder habits, vaginal dryness or narrowing, and long-term pelvic tissue changes, which are carefully managed through supportive care and follow-up. Chemotherapy plays a particularly important role in the treatment of advanced-stage uterine cancer, aggressive histologic subtypes such as uterine serous carcinoma or clear cell carcinoma, and recurrent disease, and it involves the use of anti-cancer drugs, most commonly administered intravenously, that circulate throughout the body to kill cancer cells that may have spread beyond the uterus.

The most frequently used chemotherapy regimens include combinations of drugs such as carboplatin and paclitaxel, which have been shown to improve survival outcomes, although chemotherapy can also cause side effects including nausea, hair loss, fatigue, lowered blood counts, increased risk of infection, neuropathy, and changes in appetite, all of which are closely monitored and managed by oncology teams to maintain patient safety and comfort. Hormone therapy is another important treatment option, particularly for cancers that are hormone receptor-positive, meaning the cancer cells grow in response to estrogen or progesterone, and it is often used in patients with advanced or recurrent disease, those who cannot tolerate chemotherapy or radiation, or younger patients who wish to preserve fertility under very carefully selected circumstances and strict medical supervision. Hormone therapy works by blocking hormones or lowering hormone levels in the body and commonly involves the use of progestins, aromatase inhibitors, or drugs that affect estrogen receptors, and while it is generally associated with fewer side effects than chemotherapy, it can still cause weight gain, fluid retention, hot flashes, mood changes, and increased risk of blood clots in some patients.